金域医学(603882) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,466,504,705.88, a decrease of 20.35% compared to the same period last year[6] - The net profit attributable to shareholders was -¥27,785,254.88, representing a decline of 49.09% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥38,700,504.33, down 32.11% year-on-year[6] - The basic and diluted earnings per share were both -¥0.06, a decrease of 50.00% year-on-year[6] - Net profit for Q1 2025 was a loss of ¥34,725,978.18, compared to a loss of ¥26,419,413.39 in Q1 2024, representing a 31.5% increase in losses[30] - The total comprehensive income for Q1 2025 was a loss of ¥36,660,342.17, compared to a loss of ¥26,338,875.79 in Q1 2024[31] Cash Flow - The net cash flow from operating activities was ¥54,504,692.15, a significant increase of 139.41% compared to the previous year[6] - The net cash flow from operating activities for Q1 2025 was ¥54,504,692.15, a significant improvement from a negative cash flow of ¥138,310,819.32 in Q1 2024[36] - The net cash flow from investing activities was -97,426,897.49, compared to -97,210,373.11 in the previous period, indicating a slight increase in cash outflow[37] - Cash inflow from financing activities totaled 27,458,021.55, down from 65,159,738.92, reflecting a significant decrease of approximately 58%[37] - Cash outflow for financing activities was 429,632,269.24, compared to 174,788,077.20 in the previous period, representing an increase of about 145%[37] - The net cash flow from financing activities was -402,174,247.69, worsening from -109,628,338.28 in the previous period[37] - The impact of exchange rate changes on cash and cash equivalents was -1,510,271.71, contrasting with a positive impact of 203,344.80 previously[37] - The net increase in cash and cash equivalents was -446,606,724.74, compared to -344,946,185.91 in the previous period, indicating a larger decline[37] - The ending balance of cash and cash equivalents was 1,975,917,824.88, down from 2,104,727,955.32, reflecting a decrease of approximately 6%[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,854,909,916.16, a decrease of 5.17% from the end of the previous year[6] - The company's current assets totaled ¥6,818,528,334.74, down from ¥7,318,237,550.29, indicating a decrease of about 6.86%[22] - The cash and cash equivalents decreased to ¥1,987,068,521.84 from ¥2,433,585,245.93, reflecting a decline of approximately 18.36%[21] - Accounts receivable stood at ¥4,321,276,982.00, slightly down from ¥4,396,328,960.56, showing a decrease of about 1.70%[21] - The total liabilities decreased to ¥2,837,464,947.26 from ¥2,916,821,149.44, which is a reduction of approximately 2.71%[24] - The company's non-current liabilities totaled ¥690,242,205.53, a slight increase from ¥684,406,029.88, indicating a rise of about 0.12%[24] - The total equity remained stable at ¥7,017,444,968.90, unchanged from the previous period[24] - The total equity attributable to shareholders of the parent company decreased to ¥6,887,883,046.28 from ¥7,325,269,947.15, reflecting a decline of 6.0%[25] - As of March 31, 2025, the total assets of the company amounted to ¥9,854,909,916.16, a decrease from ¥10,391,893,742.49 as of December 31, 2024, representing a decline of approximately 5.14%[21] Operational Efficiency and Strategy - The gross profit margin increased by 1.16 percentage points compared to the previous year[7] - The company is focusing on long-term development through differentiated services and cost leadership strategies to enhance competitiveness[7] - The company aims to improve operational efficiency through digital transformation and automation in production processes[7] - Research and development expenses for Q1 2025 were ¥77,105,975.66, down 16.3% from ¥92,123,715.26 in Q1 2024[29] - The company has invested ¥4,236,639.48 in development expenditures, up from ¥3,354,408.43, indicating an increase of about 26.19%[23] - The company’s goodwill remained constant at ¥52,205,371.01, with no change from the previous reporting period[23] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[38]